Curbstone Financial Management Corp Sells 526 Shares of Eli Lilly and Company (NYSE:LLY)

Curbstone Financial Management Corp lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,520 shares of the company’s stock after selling 526 shares during the quarter. Curbstone Financial Management Corp’s holdings in Eli Lilly and Company were worth $3,527,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Eli Lilly and Company by 4.8% during the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock worth $28,449,000 after acquiring an additional 3,768 shares during the last quarter. L2 Asset Management LLC lifted its position in Eli Lilly and Company by 4.5% in the first quarter. L2 Asset Management LLC now owns 2,014 shares of the company’s stock worth $692,000 after buying an additional 86 shares during the last quarter. Patten & Patten Inc. TN boosted its stake in Eli Lilly and Company by 44.2% during the first quarter. Patten & Patten Inc. TN now owns 17,177 shares of the company’s stock worth $5,899,000 after buying an additional 5,266 shares during the period. Missouri Trust & Investment Co raised its stake in shares of Eli Lilly and Company by 3.2% in the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock valued at $266,000 after acquiring an additional 24 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $859,000. 81.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LLY shares. Royal Bank of Canada upped their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Argus increased their price target on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. UBS Group boosted their price objective on Eli Lilly and Company from $447.00 to $498.00 and gave the company a “buy” rating in a report on Wednesday, May 24th. Bank of America increased their target price on Eli Lilly and Company from $500.00 to $600.00 in a research note on Wednesday, August 9th. Finally, The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Stock Up 0.3 %

LLY stock traded up $1.97 during trading on Thursday, reaching $600.85. 689,832 shares of the company traded hands, compared to its average volume of 3,007,675. The business has a 50 day simple moving average of $504.85 and a 200 day simple moving average of $433.48. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $601.84. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The company has a market capitalization of $570.38 billion, a price-to-earnings ratio of 83.29, a price-to-earnings-growth ratio of 2.36 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same period in the prior year, the firm posted $1.25 earnings per share. The company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and Company will post 9.83 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were paid a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio (DPR) is 62.87%.

Insiders Place Their Bets

In other news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares in the company, valued at approximately $4,586,004.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,156 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the transaction, the insider now owns 101,387,286 shares in the company, valued at approximately $46,037,938,826.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,010,309 shares of company stock valued at $21,095,701,670. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.